Fujirebio wins ANVISA clearance in Brazil for Lumipulse blood-based neurology assays

• Fujirebio, a unit of H.U. Group Holdings, secured ANVISA market authorization in Brazil for Lumipulse G NfL Blood.
• Authorization also covers Lumipulse G pTau 217 Plasma, expanding access to blood-based neurology biomarker testing on the LUMIPULSE G platform.
• Clearance builds on existing CE-marked IVD status, supporting broader rollout of Fujirebio’s neurology diagnostics portfolio in Brazil.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. H.U. Group Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609140100BIZWIRE_USPR_____20260913_BW014027) on September 14, 2026, and is solely responsible for the information contained therein.